Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)<br /> Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
-
Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Background:
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 3
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 4
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 5
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 6
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Related Documents
